

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**



In re Application of  
**PARKAR, et al.**

Application No.: **10/747,994**

Examiner: Not Yet Known

Art Unit: Not Yet Known

Filed: **December 30, 2003**

Title: **NUCLEIC ACID ENCODING A  
NOVEL PROSTAGLANDIN  
RECEPTOR PROTEIN AND  
METHODS OF USE THEREOF**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 15, 2004

Date of Deposit

Signature


*Joel B. German, Sr.*

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE  
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Mail Stop Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" part of the enclosed patent application required by 37 C.F.R. 1.821 (c) and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same.

Respectfully submitted,

  
Joel B. German, Reg. No. 48,676  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-3444  
Telefax (908) 231-2626

Aventis Docket No. USAV2003/0073 US NP